Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2013-07-04 AGM Information
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i Orexo
AGM Information Classification · 1% confidence The document is titled "Kallelse till extra bolagsstämma i Orexo" (Notice of Extraordinary General Meeting in Orexo). It details the date, time, location, registration procedures, and the proposed agenda for an Extraordinary General Meeting (EGM). The agenda items specifically concern decisions regarding changes to a long-term incentive program (LTIP) and the issuance of warrants to cover obligations under that program. This content—a formal notice calling shareholders to a meeting to vote on specific corporate actions—is characteristic of materials related to a General Meeting. Since it is a notice calling for a vote, it is most closely related to the process leading up to a shareholder vote, which aligns best with the context of an AGM/EGM notice, even though the specific content deals with compensation/capital structure. Given the options, 'AGM-R' (AGM Information) is the most appropriate category for the notice and materials related to a General Meeting, even if it is an 'Extra' meeting, as it serves the same function as an AGM notice in terms of shareholder participation and voting on corporate matters. It is not a DEF 14A (Remuneration Information) because it is the *notice* calling the meeting to *decide* on the remuneration plan, not the final remuneration report itself. It is also not a CAP (Capital/Financing Update) because the primary document type is the meeting notice itself.
2013-07-04 Swedish
Antal aktier och röster i Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release (1425 chars) dated July 2, 2013, titled 'Antal aktier och röster i Orexo' (Number of shares and votes in Orexo). It explicitly states that the number of shares and votes has changed due to the exercise of stock options and provides the total count as of the last trading day of June. This content directly relates to changes in the total number of outstanding shares, which falls under Capital/Financing updates or Share Issue/Capital Change. Given the specific nature of reporting the total share count change, 'Share Issue/Capital Change' (SHA) is the most precise fit, as it details a change in the capital structure via option exercise. It is not a general regulatory filing (RNS) because it fits a specific category (SHA).
2013-07-02 Swedish
Number of shares and votes in Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated July 2, 2013, announcing a change in the 'Number of shares and votes in Orexo' due to the exercise of warrants. This directly relates to a change in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) covers announcements regarding new share issues or capital changes. Although the text mentions warrants being exercised (which often leads to new shares), the core subject is the resulting change in the total number of shares and votes. This fits best under SHA, as it is a direct notification of a capital structure event, rather than a general regulatory filing (RNS) or a director's dealing (DIRS). The document length is short, but the content is a specific announcement, not just an announcement *of* another report.
2013-07-02 English
Orexo ingår kommersiellt partnerskap med Publicis Touchpoint Solutions för lanseringen av Zubsolv™ i USA
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Pressmeddelande" (Press Release) in Swedish and announces a significant business event: Orexo entering a commercial partnership with Publicis Touchpoint Solutions for the launch of Zubsolv in the USA. It includes details about the agreement, financial structure, and schedules a conference call. This type of announcement, detailing strategic business developments, partnerships, or major operational news outside of routine financial reporting (like 10-K or ER), typically falls under general regulatory announcements or news releases. Since it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a capital event (CAP, SHA), the most appropriate general category for a significant, non-standard regulatory announcement is 'Regulatory Filings' (RNS), which serves as a broad category for such disclosures when a more specific code doesn't apply. The document length (6926 chars) is substantial enough that it is the primary announcement itself, not just a brief notice of publication (RPA).
2013-07-01 Swedish
Orexo Appoints Robert A. DeLuca as President of Orexo US Inc.
Board/Management Information Classification · 1% confidence The document is explicitly titled as a "Press release" and announces the appointment of a new President for the US subsidiary, including details about the executive's background and the strategic importance of this hire for the upcoming launch of Zubsolv™. This type of announcement, concerning changes in senior management, directly corresponds to the definition of Board/Management Information. Filing Type Code: MANG (Board/Management Information). The document length (4936 chars) is substantial enough that it is not merely a brief announcement of a report (RPA/RNS), but the content itself is focused on personnel change.
2013-07-01 English
First patient dosed in new phase III study targeted towards a future clinical indication expansion for Zubsolv
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a specific corporate event: dosing the first patient in a Phase III study for a drug indication expansion. This type of announcement, detailing clinical trial progress and future regulatory steps (FDA application), is a standard form of corporate news release. It is not a comprehensive annual report (10-K), an interim report (IR), a formal earnings release (ER) focusing on financial figures, or a presentation (IP). Since it is a general announcement of corporate activity that doesn't fit the highly specific categories like DIRS, DIV, or CAP, it falls best under the general Regulatory Filings (RNS) category, which serves as a fallback for significant, non-financial, non-meeting related corporate news releases.
2013-06-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.